APM logo: click to return home Academy of Psychosomatic Medicine
Psychiatrists Providing Collaborative Care Bridging Physical and Mental Health


Home > Library > Annotated Journal Abstracts > 2016 Q4: HIV Psychiatry

Annotated Abstracts of Journal Articles
2016, 4th Quarter

HIV Psychiatry

Annotations by John Grimaldi, MD and Mary Ann Cohen, MD, FAPM
January 2017

  1. HIV-associated cognitive impairment in perinatally infected children: A meta-analysis
  2. Cognitive behavioural therapy for adherence and depression in patients with HIV: A three-arm randomised controlled trial
Also of interest:
  • Hartzler B, Dombrowski JC, Crane HM, Eron JJ, Geng EH, Mathews WC, et al: Prevalence and predictors of substance use disorders among HIV care enrollees in the United States
    AIDS Behav 2016 Oct 13 [Epub ahead of print]

    Drawing on data from The Center for AIDS Research Network of Integrated Clinical Systems, this study estimated the prevalence of substance use disorders (SUD) and associated demographic risk factors for a cohort of 10,652 HIV-positive adults receiving HIV care at seven sites. Findings were as follows: 1) overall SUD prevalence was 48%; 20% of the aggregate sample reached thresholds for multiple substances; 2) prevalence for specific substance UDs were 31% for marijuana, 19% for alcohol, 13% for methamphetamine, 11% for cocaine, and 4% for opioid; 3) in a multivariable model, younger age and male gender were associated with having any SUD. This study is consistent with and extends findings from the only other multisite study of SUD prevalence, the HIV Cost and Services Utilization Study (HCSUS) of 2864 adults receiving HIV care in 1996. A strength of the current study was the use of SUD screening instruments with validated diagnostic thresholds. Given the negative effect of SUDs across the full continuum of HIV care, the importance of defining the scope and developing effective therapies for SUDs cannot be overstated.
PUBLICATION #1 — HIV Psychiatry
HIV-associated cognitive impairment in perinatally infected children: A meta-analysis
Phillips N, Amos T, Kuo C, Hoare J, Ipser J, Thomas KG, et al
Pediatrics 2016; 138(5)
Annotation

The finding: The aim of this systematic review and meta-analysis was to assess the impact of HIV on neurocognitive performance in perinatally HIV-infected children and adolescents compared to HIV exposed but uninfected and HIV-uninfected controls. Findings from the meta-analysis showed a statistically significant effect in between-group comparisons for 2 out of the 10 neurocognitive domains tested; executive function and processing speed were significantly more impaired. Effect size estimates were also calculated for between-group comparisons for each cognitive domain. Executive functioning and processing speed showed significant differences between groups. Additionally, when ranked according to effect size, working memory, processing speed, and executive functioning showed the largest between-group differences. Of the 22 studies that met inclusion criteria in the study, 6 were eligible for the meta-analysis. The remaining 16 studies were looked at qualitatively. Among these studies group differences were found for executive functioning, processing speed, working memory, and visual memory.

Strength and weaknesses: Strong evidence exists supporting the negative effect of HIV on global cognitive functioning in perinatally HIV-infected children and adolescents. This study fills an important gap in knowledge about the extent of cognitive impairment and which specific domains are most likely to be affected. Data sources included five electronic bibliographic databases. This study also used mean-effect size estimates to calculate the strength of the association between domain-specific impairment and HIV, enabling ranking of the domains in order of degree of impairment. The burden of perinatal HIV is greatest in sub-Saharan Africa, yet the majority of studies included occurred in developed countries. This disparity limits the generalizability of findings to resource challenged areas.

Relevance: Despite the overwhelming success of prevention of mother-to-child HIV transmission in developed countries, vertical transmission in resource-challenged areas remains problematic. Furthermore the relative paucity of knowledge about the degree of domain-specific cognitive impairment has been a barrier to the development of effective therapies. Individuals with perinatally acquired HIV are unique in that degeneration is occurring during rapid brain growth and development. Therefore the characterization of impairments may lead to better prevention and treatment approaches tailored to the needs of this vulnerable group.

PUBLICATION #2 — HIV Psychiatry
Cognitive behavioural therapy for adherence and depression in patients with HIV: A three-arm randomised controlled trial
Safren SA, Bedoya CA, O'Cleirigh C, Biello KB, Pinkston MM, Stein MD, et al
Lancet HIV 2016; 3(11):e529-e538
Annotation

The finding: This study used a three-arm design to randomly assign HIV-positive adults with depression to receive 1) CBT for depression combined with a cognitive behavioral approach to enhance antiretroviral medication adherence (Life-Steps), CBT-AD; or 2) integrated supportive psychotherapy with Life-Steps adherence counseling, ISP-AD; or 3) a control group intervention comprising enhanced treatment as usual and Life-Steps, ETAU. The primary outcome was antiretroviral medication adherence at 4 months follow-up assessed via electronic pill bottle cap, Medication Event Monitoring System (MEMS). Secondary outcomes were depression severity as assessed with CESD, MADRS, and CGI scales, HIV RNA and CD4 cell count, at 4, 8, and 12 months follow-up visits. The results showed that CBT-AD outperformed ETAU on both depression and adherence measures at the end of the 4-month treatment period and subsequent 8-month follow-up. There was no significant difference in primary or secondary outcomes between the CBT-AD and ISP-AD arms. The authors conclude that integrating adherence counseling and evidence-based depression treatment offers advantages in HIV-positive individuals suffering from depression.

Strength and weaknesses: This full-scale efficacy trial extends positive findings from previous smaller trials and uses two active intervention arms as well as a less intensive comparison group. Findings can be used to inform cost-effective design of integrated HIV behavioral health care programs. The study included individuals who were virologically suppressed at baseline, thus limiting detection of an intervention effect with respect to secondary biological outcome measures. In addition, the use of a MEMS cap to assess adherence may result in either underestimation or overestimation of adherence. The use of three study sites expanded the potentially available participants. However, location of sites in medical centers in the northeast in the USA limit generalizability of findings to less resource-rich areas. Similarly, the high level of training of staff supervising the treating clinicians limits the exportability of treatment.

Relevance: Effective HIV prevention depends on expanded HIV testing, engagement, and retention in care and adherence to antiretroviral medication which is essential for virologic suppression. Depression is highly prevalent in HIV-infected individuals and can disrupt success at any point along the continuum of care. In addition, treatment of depression alone will not insure adequate adherence to HIV medication regimens. This study adds to our current understanding of evidence-based interventions that target both depression and adherence and which can be adapted to a variety of settings. The study also offers insight into the specific kinds of interventions that may be required.


Home  •  About  •  Join  •  Members  •  News  •  Annual Meeting  •  Career  •  Education  •  Support


© Academy of Psychosomatic Medicine
JavaScript menu courtesy of Milonic.com